1-tert-butyl (2S,4R)-2-(aminocarbonyl)-4-[(methylsulfonyl)oxy]pyrrolidine-1-carboxylate | 127423-45-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-tert-butyl (2S,4R)-2-(aminocarbonyl)-4-[(methylsulfonyl)oxy]pyrrolidine-1-carboxylate
• 英文别名: (2S,4R)-1-(t-butoxycarbonyl)-2-carbamoyl-4-methanesulfonyloxypyrrolidine；(2S, 4R)-1-(t-Butoxycarbonyl)-2-carbamoyl-4-methanesulfonyloxypyrrolidine；tert-butyl (2S,4R)-2-carbamoyl-4-methylsulfonyloxypyrrolidine-1-carboxylate
• CAS: 127423-45-4
• 化学式: C₁₁H₂₀N₂O₆S
• 分子量: 308.356
• InChiKey: BMTOHCLRAIEVPW-SFYZADRCSA-N

物化性质

• 沸点：
  531.3±50.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-tert-butyl (2S,4R)-2-(aminocarbonyl)-4-[(methylsulfonyl)oxy]pyrrolidine-1-carboxylate 在 四丁基氟化铵 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 60.0h， 生成 (2S,4S)-2-氨基甲酰基-4-氟吡咯烷-1-羧酸叔丁酯
  参考文献：
  名称：

  WO2008/1195

  摘要：

  公开号：
• 作为产物：
  描述：

  N-Boc-反式-4-羟基-L-脯氨酸甲酯 在 氨 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-tert-butyl (2S,4R)-2-(aminocarbonyl)-4-[(methylsulfonyl)oxy]pyrrolidine-1-carboxylate
  参考文献：
  名称：

  cis-2,5-Dicyanopyrrolidine Inhibitors of Dipeptidyl Peptidase IV:  Synthesis and in Vitro, in Vivo, and X-ray Crystallographic Characterization

  摘要：

  Inhibitors of the glucagon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be effective treatments for type 2 diabetes in animal models and in human subjects. A novel series of cis-2,5-dicyanopyrrolidine alpha-amino amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. 1-({[1-(Hydroxymethyl) cyclopentyl] amino}acetyl) pyrrolidine-2,5-cis-dicarbonitrile (1c) is an achiral, slow-binding (time-dependent) inhibitor of DPP-IV that is selective for DPP-IV over other DPP isozymes and proline specific serine proteases, and which has oral bioavailability in preclinical species and in vivo efficacy in animal models. The mode of binding of the cis-2,5-dicyanopyrrolidine moiety was determined by X-ray crystallography. The hydrochloride salt of 1c was further profiled for development as a potential new treatment for type 2 diabetes.

  DOI：

  10.1021/jm0600085

文献信息

• 2-(heterocyclylthio)carbapenem derivatives, their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05104867A1

  公开（公告）日：1992-04-14

  Compounds of formula (I): ##STR1## in which R.sup.a is a group of formula (II): ##STR2## or a group of formula (III): ##STR3## (where one of R' is a bond to the remainder of the compound, one more of R' is R.sup.2 and the others of R' are all hydrogen), R.sup.1 is hydrogen or methyl, R.sup.2 is hydrogen, optionally substiuted alkyl, halogen, hydroxy, alkoxy, amino, alkanoylamino, alkanoyloxy, alkanoyl, carboxy, alkoxycarbonyl, cyano, --S(O).sub.j R.sup.9 (where j is 0, 1 or 2 and R.sup.9 is alkyl), or --CONR.sup.6 R.sup.7 (which is optionally substituted carbamoyl or heterocyclyl-carbonyl), R.sup.2a is hydrogen, alkyl or alkanoyl, --NR.sup.3 R.sup.4 is optionally substituted amino or heterocyclic, and --COOR.sup.5 is carboxy, --COO.sup.-, --COOM.sub.x (where M is a cation and x is the reciprocal of the valence of the cation M) or protected carboxy and, where --COOR.sup.5 is carboxy, --COOM.sub.x or protected carboxy, the compound of formula (I) also contains an anion; l, m and n are independently 0, 1, 2 or 3, provided that (m+n) is an integer from 2 to 6; p is 0, 1 or 2; Y is a single bond, oxygen, sulfur or R.sup.8 N<(wherein R.sup.8 is hydrogen, alkyl or alkanoyl) and pharmaceutically acceptable salts and esters thereof are potentially valuable antibiotics.

  公式（I）的化合物：其中R.sup.a是公式（II）的一个基团：或者是公式（III）的一个基团：（其中R'之一是与化合物的其余部分相连的键，R'中的一个以上是R.sup.2，其余的R'都是氢），R.sup.1是氢或甲基，R.sup.2是氢，可选择地是取代的烷基，卤素，羟基，烷氧基，氨基，烷酰胺基，烷酰氧基，烷酰基，羧基，烷氧羰基，氰基，-S（O）.sub.j R.sup.9（其中j为0、1或2，R.sup.9为烷基），或者-CONR.sup.6 R.sup.7（可选择地是取代的氨基甲酰基或杂环酰基），R.sup.2a是氢，烷基或烷酰基，-NR.sup.3 R.sup.4是可选择地取代的氨基或杂环基，-COOR.sup.5是羧基，-COO^.-，-COOM.sub.x（其中M是阳离子，x是阳离子M的价的倒数）或者保护羧基，其中-COOR.sup.5是羧基，-COOM.sub.x或者保护羧基时，化合物的公式（I）还包含一个阴离子；l、m和n独立地为0、1、2或3，只要（m+n）是从2到6的整数；p为0、1或2；Y是单键，氧，硫或R.sup.8 N<（其中R.sup.8是氢，烷基或烷酰基）及其药学上可接受的盐和酯可能是有价值的抗生素。
• 2-(heterocyclylthio) carbapenem derivatives, their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05242914A1

  公开（公告）日：1993-09-07

  Compounds of formula (I): ##STR1## in which R.sup.a is a group of formula (II): ##STR2## where one of R' is a bond to the remainder of the compound, one more of R' is R.sup.2 and the others of R' are all hydrogen, R.sup.1 is hydrogen or methyl, R.sup.2 is hydrogen, optionally substituted alkyl, halogen, hydroxy, alkoxy, amino, alkanoylamino, alkanoyloxy, alkanoyl, carboxy, alkoxycarbonyl, cyano, --S(O).sub.j R.sup.9 where j is 0, 1 or 2 and R.sup.9 is alkyl, or --CONR.sup.6 R.sup.7 which is optionally substituted carbamoyl or heterocyclyl-carbonyl, --NR.sup.3 R.sup.4 is optionally substituted amino or heterocyclic, and --COOR.sup.5 is carboxy, --COO.sup.-, --COOM.sub.x, where M is a cation and x is the reciprocal of the valence of the cation M or protected carboxy and, where --COOR.sup.5 is carboxy, --COOM.sub.x or protected carboxy, the compound of formula (I) also contains an anion; l, m and n are independently 0, 1, 2 or 3, provided that (m+n) is an integer from 2 to 6; p is 0, 1 or 2; Y is a single bond, oxygen, sulfur or ##STR3## wherein R.sup.8 is hydrogen, alkyl or alkanoyl, and pharmaceutically acceptable salts and esters thereof. Such compounds are useful as antibiotics.

  式(I)的化合物：##STR1## 其中R.sup.a是式(II)的基团：##STR2## 其中R'中的一个是与化合物的其余部分成键的键，R'中的一个或多个是R.sup.2，其余的R'都是氢，R.sup.1是氢或甲基，R.sup.2是氢、可选取代的烷基、卤素、羟基、烷氧基、氨基、烷酰胺基、烷酰氧基、烷酰基、羧基、烷氧羰基、氰基、--S(O).sub.jR.sup.9（其中j为0、1或2，R.sup.9为烷基）或--CONR.sup.6R.sup.7（可选取代的氨基甲酰基或杂环基甲酰基），--NR.sup.3R.sup.4是可选取代的氨基或杂环基，--COOR.sup.5是羧基、--COO.sup.-、--COOM.sub.x（其中M为阳离子，x为阳离子M的价的倒数）或保护羧基，如果--COOR.sup.5是羧基、--COOM.sub.x或保护羧基，则式(I)的化合物还包含一个阴离子；l、m和n独立地为0、1、2或3，但(m+n)是2到6的整数；p为0、1或2；Y是单键、氧、硫或##STR3## 其中R.sup.8是氢、烷基或烷酰基，以及其药学上可接受的盐和酯。这些化合物可用作抗生素。
• NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS
  申请人：Thomas Abraham

  公开号：US20080076818A1

  公开（公告）日：2008-03-27

  The present invention relates to novel processes for preparing DPP-IV inhibitors having the structure of formula I, and pharmaceutically acceptable salt thereof, which are useful for treatment of Type 2 diabetes.

  本发明涉及一种新型制备DPP-IV抑制剂的方法，其具有公式I的结构和药学上可接受的盐，对于治疗2型糖尿病具有用处。
• Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors
  作者：Ljubomir Isakovic、Oscar M. Saavedra、David B. Llewellyn、Stephen Claridge、Lijie Zhan、Naomy Bernstein、Arkadii Vaisburg、Nadine Elowe、Andrea J. Petschner、Jubrail Rahil、Norman Beaulieu、France Gauthier、A. Robert MacLeod、Daniel Delorme、Jeffrey M. Besterman、Amal Wahhab

  DOI：10.1016/j.bmcl.2009.03.132

  日期：2009.5

  Potent SAH analogues with constrained homocysteine units have been designed and synthesized as inhibitors of human DNMT enzymes. The five membered (2S,4S)-4-mercaptopyrrolidine-2-carboxylic acid, in 1a, was a good replacement for homocysteine, while the corresponding six-member counterpart was less active. Further optimization of 1a, changed the selectivity pro. le of these inhibitors. A Chloro substituent at the 2-position of 1a, compound 1d, retained potency against DNMT1, while N-6 alkylation, compound 7a, conserved DNMT3b2 activity. The concomitant substitutions of 1a at both 2- and N-6 positions reduced activity against both enzymes. (C) 2009 Elsevier Ltd. All rights reserved.
• KAVAMOTO, ISAO;TANAKA, TEHRUO;EHNDO, ROKURO;IVATA, MASAYUKI
  作者：KAVAMOTO, ISAO、TANAKA, TEHRUO、EHNDO, ROKURO、IVATA, MASAYUKI

  DOI：——

  日期：——